The global market for generic drugs estimated at $430.2 billion in 2023, is projected to reach a revised size of $671.5 billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030, ...
ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To ...
TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API ...
Teva announced its intention to divest its active-pharmaceutical ingredient business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees ...
Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...
Strong R&D investment, advanced manufacturing technologies, and supportive government policies accelerate global API production growth.Austin, Texas, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Small Molecule ...
Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...
Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...
Founded in 1901, Teva emerged as a small wholesale drug business in Jerusalem that was converted into a local drug manufacturer during World War II with the rise in demand. The company consolidated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback